Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate [3]

Kidney International

Volumn 72, Issue 9, 2007, Pages 1162-1163

  Aime, S ^a   Canavese, C ^b   Stratta, P ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM CHELATE; LANTHANUM CARBONATE;

BLOOD; DRUG SAFETY; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MASS; NEPHROLOGIST; PHYSIOLOGY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK; UREMIA;

CHELATING AGENTS; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LANTHANUM; SKIN DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UREMIA;

EID: 35349028390     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002503     Document Type: Letter

References (5)

1. FDA. Public Health Advisory - Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available at: http://www.fda.gov/cder/drug/advisory/ gadolinium_agents.htm Accessed May, 2007.
2. Cabella C, Crich SG, Corpillo D et al. Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ions. Contrast Media Mol Imaging 2006; 1: 23-29.
3. Evans CH. Biochemistry of the Lanthanides. Plenum Press: New York and London, 1990.
4. Canavese C, Mereu C, Nordio M et al. Blast from the past: the aluminum's ghost on the lanthanum salts. Curr Med Chem 2005; 12: 1631-1636.
5. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2006; 68: 2809-2813.